In a study published in Cancer Discovery, researchers from the Wistar Institute reported a key mechanism as to how p53 suppresses tumors. By comparing the mechanisms of wildtype and variant p53, the researchers discovered the mechanism by which p53 triggers immune function that, in turn, kills the tumor.
The Wistar Institute is collaborating with Accelerated Biosciences Corp. to create a platform based on human trophoblast stem cells to explore new immunotherapies that use Accelerated Bio’s proprietary technology. This collaboration could generate various types of immune cells from hTSCs, changing the field of allogeneic immunotherapies.
